Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Trastuzumab deruxtecan + SRS in brain metastases
T-DXd combined with SRS:
- Did not increase radionecrosis risk
- Improved intracranial disease control
However…
Key limitations of this study:
- Retrospective design
- Small sample size (especially T-DXd cohort)
- Shorter follow-up in T-DXd group (late RN may be missed)
- Dosimetric imbalances (smaller lesions, lower RT doses)
- Heterogeneous control group (including T-DM1)
- Potential immortal time bias
Bottom line:
- Promising results
- But not sufficient to conclude this combination is fully safe in routine practice yet.”
Title: Impact of Trastuzumab Deruxtecan (T-DXd) and Brain Stereotactic Radiosurgery on Intracranial Control and Radionecrosis Risk in HER2-Positive or -Low Breast Cancer Brain Metastases
Authors: Seok-Joo Chuna, Kyubo Kimb, Won Ick Changc, Yong Bae Kimd, Sun Ha Paeke, Kyung-Hun Leef, Jin-Ho Songg, Ji Hyun Hongg, Jieun Leeh, Won Il Jangi, Tae Hyun Kimj, Kyung Hwan Shin.
Other articles featuring Ahmet Dirican on OncoDaily.